Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Disease-modifying HF medications can help reduce mortality risk in patients with ADHF

Elaine Soliven
21 Nov 2019

Hyperuricaemia, ejection fraction of <40 percent, and elevated NTproBNP* and urea levels appear to be associated with a significantly increased risk of mortality in patients with atrial fibrillation (AF) who were admitted for ADHF**, while the use of disease-modifying heart failure (HF) medications at admission and discharge may reduce the risk, according to a study presented at ESC Asia 2019.

“HF and AF commonly coexist, each, predisposing the other. AF may inflict haemodynamic disturbances, leading to reduced cardiac output, and hence acute decompensation. Ultimately, mortality risk is further increased. Identifying contributing factors is thus vital lest increasing risk of poor outcome,” according to the researchers.

The researchers retrospectively analysed 810 patients with AF (64.7 percent male) who were first admitted for ADHF between 2009 and 2018. [ESC Asia 2019, abstract P252]

Overall mortality rates were 5.1 percent upon admission, and 14.4 and 40.5 percent at 1 and 3 years of follow-up after hospital admission.

In a multivariate analysis, hyponatraemia of Na<135 mmol/L (adjusted odds ratio [adjOR], 2.49, 95 percent confidence interval [CI], 1.91–5.20; p=0.015), uric acid level of ≥675 µmol/L(adjOR, 2.75, 95 percent CI, 1.31–5.79; p=0.008), and ejection fraction of <40 percent (adjOR, 3.93, 95 percent CI, 1.63–9.49; p=0.002) were associated with a significant increased risk of in-hospital mortality.

At 1 year, those with NTproBNP level of ≥7,500 pg/mL (adjusted hazard ratio [adjHR], 1.64, 95 percent CI, 1.02–2.65; p=0.042) and urea level of >7 mmol/L (adjHR, 1.86, 95 percent CI, 1.04–3.32; p=0.036) had a significantly increased risk ofmortality. “[Notably,] elevated NTproBNP and urea levels seemed to have more effect on mortality at 1 year compared to 3 years,” said the researchers.

Patients who had backgroundcoronary artery disease (adjHR, 1.72, 95 percent CI, 1.09–2.71; p=0.02), hypernatraemia of Na>145 mmol/L (adjHR, 14.89, 95 percent CI, 3.17–69.86; p=0.001), and ejection fraction of <40 percent (adjHR, 2.00; 95 percent CI, 1.28–3.12; p=0.002) also demonstrated a significantly increased risk of mortality at 3 years.

However, patients who received disease-modifying HF medications, particularly ACEi/ARB + BB + MRA***, at hospital admission (adjOR, 0.07, 95 percent CI, 0.02–0.30; p<0.001) and discharge (adjHR, 0.23, 95 percent CI, 0.09–0.60; p=0.003 for 1 year and adjHR, 0.193, 95 percent CI, 0.09–0.43; p<0.001 for 3 years) had significantly reduced mortality risk.

“[Our results highlighted that] patients with AF who presented with ADHF had a variety of mortality predictors that influence at different timelines,” said the researchers.

 

*NTproBNP: N-terminal pro b-type natriuretic peptide

**ADHF: Acute decompensated heart failure

***ACEi/ARB + BB + MRA: Angiotensin Converting Ezyme inhibitor/Angiotensin Receptor Blocker + Beta Blocker + Mineralocorticoid Receptor Antagonist

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.